Clinical Trial Update: Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update indicates Gedatolisib in combination with Darolutamide is being studied in metastatic castration-resistant prostate cancer, currently in P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)
• Gedatolisib (gedatolisib)

Snippet

Sponsor: Celcuity Inc | Conditions: mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male | Phase 1, Phase 2 | Status: RECRUITING